Evaluation of tolerability safety, and pharmacokinetics of hOKT3g1 (Ala-Ala) [teplizumab]
Phase of Trial: Phase I
Latest Information Update: 19 Jan 2010
At a glance
- Drugs Teplizumab (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions
- 19 Jan 2010 Actual end date (Dec 2005) added as reported by ClinicalTrials.gov.
- 06 Dec 2007 Status changed from in progress to completed.
- 22 Oct 2005 New trial record.